Singapur - anglès - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - tamoxifen citrate 30.4mg eqv tamoxifen - tablet, film coated - 20 mg - tamoxifen citrate 30.4mg eqv tamoxifen 20 mg

Uganda - anglès - National Drug Authority

astrazeneca - tamoxifen - oral solid ordinary film-coated tablets - 20mg

Kenya - anglès - Pharmacy and Poisons Board

astrazeneca parklands alderley park macclesfield cheshire - tamoxifen citrate - tablet - each tablet contains tamoxifen citrate 30.4 mg… - hormone antagonists and related agents:

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - tamoxifen citrate - oral tablet - 20mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - tamoxifen citrate - oral tablet - 20mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - tamoxifen citrate - oral tablet - 20mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - tamoxifen citrate - oral tablet - 20mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - tamoxifen citrate - oral tablet - 20mg

Canadà - anglès - Health Canada

astrazeneca canada inc - tamoxifen (tamoxifen citrate) - tablet - 20mg - tamoxifen (tamoxifen citrate) 20mg - antineoplastic agents

Estats Units - anglès - NLM (National Library of Medicine)

synthon pharmaceuticals, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole tablets are contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using anastrozole tablets. if anastrozole tablets are used during pregnancy, or if the patient becomes